#Global Epilepsy Drugs Market
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Tumblr has been banned in Indonesia for providing people with access to pornographic content.
Text
Epilepsy Drugs Market will be reach US$ 10.28 Billion by 2030
Referred to as antiepileptic drugs, these medications are important for dealing with epilepsy by controlling and preventing seizures. They use diverse brain mechanisms to alter strange electrical activity. Examples consist of phenytoin, carbamazepine, valproic acid, clonazepam, ethosuximide, and levetiracetam. These drugs stabilize brain electrical activity, decreasing seizure frequency and…
View On WordPress
#epilepsy drugs market#epilepsy drugs market by drug category#epilepsy drugs market by seizure types#epilepsy drugs market share#epilepsy drugs market size#global epilepsy drugs market
0 notes
Text
https://www.pharmanucleus.com/reports/epilepsy-therapeutics-market
#Epilepsy Therapeutics Market#Epilepsy treatment#antiepileptic drugs#seizure management#epilepsy research#neurology#therapeutic options#global market trends#epilepsy medications#patient care#epilepsy therapy
0 notes
Text
Revolutionizing Drug Development: How the Clinical Trials Market is Evolving
Clinical Trials Industry Overview
The global clinical trials market size is expected to reach USD 123.5 billion by 2030, expanding at a CAGR of 6.49% from 2024 to 2030, according to a new report by Grand View Research, Inc. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and products. The market witnessed a decline of 6% in 2020 owing to the COVID-19 pandemic. However, the market is projected to recover from 2021 onwards. In addition, clinical trials have become increasingly costly, adding to the overall cost of developing a drug
.
The increasing need for developing new drugs for chronic diseases, such as cancer, respiratory disorders, diabetes, cardiovascular diseases, and others, is creating immense pressure on the healthcare industry. The COVID-19 pandemic and the increasing demand for developing a suitable treatment are driving the market. The high number of people affected by the disease further depicts an increasing need for therapeutics & vaccines. Currently, there are 288 therapeutics and 106 vaccines under development, out of which, nearly 7.0% of therapeutics are in Phase IV, 21.0% in Phase III, and 43.0% & 13.0% in Phase II & Phase I, respectively.
Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market
The pandemic has resulted in the global disruption of traditional onsite clinical trials. Hence, regulatory bodies worldwide have undertaken various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the WHO to find effective treatment against COVID-19. Although the pandemic has forced many medical device & drug developers to revise the approach to such crises, integrating best practices within clinical trial procedures & adapting to virtual trials, which can support the continuous development of therapeutics.
Browse through Grand View Research's Healthcare IT Industry Research Reports.
The global data monetization solutions for healthcare payers market size was estimated at USD 398.7 million in 2024 and is expected to grow at a CAGR of 15.8% from 2025 to 2030.
The ambulatory surgery centers IT services market size was valued at USD 230.8 billion in 2024 and is anticipated to grow at a CAGR of 10.8% from 2025 to 2030.
Clinical Trials Market Segmentation
Grand View Research has segmented the global clinical trials market based on phase, study design, indication, sponsor, indication by study design, and region:
Clinical Trials Phase Outlook (Revenue, USD Billion, 2018 - 2030)
Phase I
Phase II
Phase III
Phase IV
Clinical Trials Study Design Outlook (Revenue, USD Billion, 2018 - 2030)
Interventional
Observational
Expanded Access
Clinical Trials Indication by Study Design Outlook (Revenue, USD Billion, 2018 - 2030)
Autoimmune/Inflammation
Rheumatoid Arthritis
Multiple Sclerosis
Osteoarthritis
Irritable Bowel Syndrome (IBS)
Others
Pain Management
Chronic Pain
Acute Pain
Oncology
Blood Cancer
Solid Tumors
Other
CNS Condition
Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle Regeneration
Others
Diabetes
Obesity
Cardiovascular
Others
Clinical Trials Indication Outlook (Revenue, USD Billion, 2018 - 2030)
Autoimmune/Inflammation
Interventional
Observational
Expanded Access
Pain Management
Interventional
Observational
Expanded Access
Oncology
Interventional
Observational
Expanded Access
CNS Condition
Interventional
Observational
Expanded Access
Diabetes
Interventional
Observational
Expanded Access
Obesity
Interventional
Observational
Expanded Access
Cardiovascular
Interventional
Observational
Expanded Access
Others
Interventional
Observational
Expanded Access
Clinical Trials Sponsor Outlook (Revenue, USD Billion, 2018 - 2030)
Pharmaceutical & Biopharmaceutical Companies
Medical Device Companies
Others
Clinical Trials Service Type Outlook (Revenue, USD Billion, 2018 - 2030)
Protocol Designing
Site Identification
Patient Recruitment
Laboratory Services
Bioanalytical Testing Services
Clinical Trial Data Management Services
Others
Clinical Trials Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
US
Canada
Europe
UK
Germany
France
Spain
Italy
Asia Pacific
India
Japan
China
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Key Companies profiled:
IQVIA
PAREXEL International Corporation
Pharmaceutical Product Development, LLC
Charles River Laboratory
ICON Plc
PRA Health Sciences
Syneos Health
Eli Lilly and Company
Novo Nordisk A/S
Pfizer
Clinipace
Recent Developments
In August 2023, Parexel & Partex entered a strategic partnership aimed at utilizing Artificial Intelligence (AI)-driven solutions to expedite the process of drug discovery and development for biopharmaceutical clients globally. The collaboration aimed to reduce risks associated with the assets in their respective portfolios.
In August 2023, Novo Nordisk announced to acquire Inversago Pharma. This acquisition was part of Novo Nordisk's strategic efforts to develop new therapies targeting individuals with obesity, diabetes, and other significant metabolic diseases
In April 2022, Charles River Laboratories International, Inc. disclosed its acquisition of Explora BioLabs Holdings, Inc., a leading provider of contract vivarium research services.
Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.
0 notes
Text
2024-2032 Neuroscience Market Analysis: Industry Growth & Revenue Trends
The neuroscience market is experiencing significant growth, and it is projected to reach a remarkable $67.3 billion by 2030, driven by advancements in technology, research, and healthcare systems. The market's development is attributed to increasing research and innovations in the treatment of neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. The market growth is further supported by rising investments from both private and public entities aimed at enhancing healthcare solutions in the neuroscience field. As per the latest market research report from SNS Insider, the global neuroscience market revenue is set to witness a compound annual growth rate (CAGR) of 7.2% during the forecast period from 2024 to 2030. Read More on Neuroscience Market Revenue
Technological Innovations Fueling Neuroscience Growth
Neuroscience, which encompasses a wide array of studies on the brain, spinal cord, and peripheral nervous system, has seen exponential growth in recent years, thanks to groundbreaking advancements in technology. The integration of artificial intelligence (AI) and machine learning in research and diagnosis has significantly improved the understanding of various neurological disorders. These technological innovations are aiding in the discovery of novel therapeutic solutions and improving the accuracy of neurological diagnoses, leading to better patient outcomes.
Furthermore, the adoption of non-invasive techniques such as transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) is driving the growth of the market. These technologies have shown promising results in treating various brain-related conditions and disorders, including depression, epilepsy, and chronic pain.
Key Market Drivers and Restraints
The neuroscience market's growth is being propelled by a number of factors, including the increasing prevalence of neurological disorders. According to the World Health Organization (WHO), neurological disorders account for a significant share of the global disease burden, with over 1 billion people worldwide suffering from some form of neurological condition. This growing demand for effective treatments is expected to drive market growth in the coming years.
In addition to rising neurological disease incidences, the increasing geriatric population is also contributing to market expansion. Elderly individuals are more prone to conditions such as Alzheimer’s, dementia, and Parkinson’s, thus increasing the demand for neuroscience-related healthcare services. Moreover, the advancements in personalized medicine and the growing focus on brain health have enhanced the appeal of neuroscience as a field of research and development.
However, challenges such as the high cost of neurological treatments and the complexity of drug development processes may hinder the growth of the market. The research and development (R&D) in the neuroscience industry requires significant investments in both time and money, which could potentially slow down market growth. Additionally, the lack of skilled professionals in this specialized field poses another barrier to the market’s expansion.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/3936
Market Segmentation and Key Insights
The neuroscience market is segmented based on technology, application, and geography. Among the various technologies, neurostimulation devices are expected to witness the highest growth due to their effectiveness in managing chronic neurological conditions. The market is also being driven by increasing investments in neuroimaging technologies for precise brain mapping, which plays a crucial role in diagnostics and treatment planning.
By application, the market is divided into segments such as neurological disorder treatment, diagnostic tools, and neurorehabilitation therapies. The neurological disorder treatment segment holds the largest market share, driven by the high prevalence of diseases like Alzheimer’s and Parkinson’s. Moreover, the neurorehabilitation market is anticipated to grow at a rapid pace due to the increasing demand for post-surgical therapies and rehabilitation.
Geographically, North America holds the largest market share, owing to the presence of established healthcare infrastructure, a high incidence of neurological disorders, and strong government support for research. However, Asia-Pacific is expected to grow at the fastest rate, owing to the growing healthcare expenditure and improving healthcare facilities in countries like China and India.
Competitive Landscape
The neuroscience market is highly competitive, with key players including Medtronic, Johnson & Johnson, Boston Scientific, and Eli Lilly and Company. These companies are focusing on strategic collaborations, acquisitions, and partnerships to enhance their product offerings and expand their market presence. Additionally, the rising trend of outsourcing clinical trials to developing nations has opened up new opportunities for these companies to reduce costs while gaining access to new markets.
Furthermore, research and development (R&D) remain a critical focus for these companies, with substantial investments being made into the development of innovative technologies and therapeutics for various neurological conditions. By staying at the forefront of technology, these companies aim to maintain their competitive edge in the rapidly evolving neuroscience market.
Conclusion
The neuroscience market is poised for significant growth, driven by advancements in research, technology, and increasing healthcare needs. As demand for effective treatments for neurological disorders continues to rise, innovations in the industry will play a pivotal role in shaping the future of healthcare. With a CAGR of 7.2%, the market is expected to reach $67.3 billion by 2030, presenting vast opportunities for stakeholders in the healthcare and research sectors.
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Akash Anand – Head of Business Development & Strategy [email protected] Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)
0 notes
Text
Sculpting Synapses: How Plastics are Redefining Neuroscience Applications
The Neuroscience Market encompasses the study of the nervous system and its impact on behavior and cognitive functions. This field covers a broad spectrum of scientific areas, from molecular and cellular studies to brain imaging and computational neuroscience. The global Neuroscience Market is expected to witness significant growth due to advancements in technology, increased investment in research, and a rising prevalence of neurological disorders such as Alzheimer's, Parkinson's, and epilepsy. The emergence of innovative diagnostic tools and treatments is also driving market expansion.
The Neuroscience Market was projected by MRFR analysis to reach 35.4 (USD Billion) in 2022. The market for neuroscience is predicted to increase from 36.9 billion USD in 2023 to 53.9 billion USD in 2032. Throughout the projection period (2024–2032), the neuroscience market's compound annual growth rate (CAGR) is projected to be about 4.3%.
The Neuroscience Market is particularly essential for understanding complex brain functions and the mechanisms underlying neurological diseases. With increased government funding, academic research, and collaboration between private and public sectors, the industry is poised for sustained growth. The growing demand for novel therapeutic approaches and diagnostics in treating neurological disorders continues to influence the dynamics of the Neuroscience Market, promoting further research and development.
Neuroscience Market Size
The size of the Neuroscience Market is projected to grow significantly in the coming years. As of 2023, the market was estimated at several billion dollars and is forecasted to grow at a compound annual growth rate (CAGR) of around 4-6% over the next decade. The market size is expected to expand due to technological advancements such as brain imaging techniques, neuromodulation devices, and wearable neurotech devices. These tools are transforming the way we diagnose and treat neurological disorders, thereby fueling the demand in the Neuroscience Market.
Increasing healthcare expenditures, rising awareness about mental health and neurological diseases, and the growing aging population contribute to the increase in Neuroscience Market size. Additionally, pharmaceutical companies are focusing on neuroscience research for developing new drugs and therapies, boosting the overall market.
Neuroscience Market Share
The Neuroscience Market share is divided among several key players who are involved in developing technologies, tools, and treatments for various neurological conditions. Major companies in the Neuroscience Market include Abbott, General Electric Healthcare, Siemens Healthineers, and Medtronic. These companies hold a significant portion of the Neuroscience Market share due to their continuous innovations in imaging techniques, neurostimulation devices, and research into neurodegenerative diseases.
The academic sector also plays a substantial role, contributing to neuroscience research and advancing scientific knowledge through collaborations with industry giants. The pharmaceutical and biotechnology industries further dominate the market share by investing in drug discovery and therapeutic development for conditions like depression, schizophrenia, and neurodegenerative diseases. Emerging startups focusing on neuroinformatics, brain-computer interfaces, and artificial intelligence applications are also gaining a share in the market.
Neuroscience Market Trends
Several key trends are shaping the future of the Neuroscience Market. First, advancements in neuroimaging technologies such as functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and magnetoencephalography (MEG) are enabling more precise diagnostics and better understanding of brain disorders. Second, the integration of artificial intelligence and machine learning in neuroscience is transforming data analysis, accelerating research, and allowing personalized treatment plans.
Third, the rise of wearable neurotechnology devices, such as brain-sensing headsets, is a growing trend in the Neuroscience Market. These devices are being used for monitoring brain activity in real time, which is valuable for both clinical research and therapeutic applications. Fourth, gene therapy and stem cell research are rapidly progressing, offering potential breakthroughs in treating neurodegenerative diseases. Lastly, the increasing focus on mental health, especially post-pandemic, is driving the demand for neuroscience-based treatments and solutions for anxiety, depression, and stress-related disorders.
Reasons to Buy Neuroscience Market Reports
Comprehensive Market Insights: The report provides in-depth insights into the global Neuroscience Market, including market size, share, growth trends, and key drivers.
Forecasting and Analytics: Neuroscience Market reports offer future projections and forecasts, enabling businesses to make informed decisions regarding investments and strategies.
Competitive Landscape: Detailed analysis of the key players in the market, including their product portfolios, business strategies, and recent developments, is provided in the reports.
Emerging Trends: Reports highlight the latest trends in neuroscience research, technological advancements, and emerging applications that are expected to shape the market's future.
Strategic Recommendations: The reports offer actionable insights and recommendations for stakeholders, helping them navigate challenges and leverage opportunities in the Neuroscience Market.
Recent Developments in the Neuroscience Market
Recent developments in the Neuroscience Market have been driven by advancements in both academic research and commercial applications. For example, there has been significant progress in non-invasive brain stimulation technologies such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). These methods are being explored as potential treatments for conditions like depression and chronic pain.
Additionally, brain-computer interface (BCI) technology is making strides, with companies like Neuralink working on direct brain interfaces that could revolutionize how we interact with machines. The development of more sophisticated brain imaging tools and computational models of the brain has also accelerated neuroscience research, making it possible to tackle previously untreatable brain disorders.
In conclusion, the Neuroscience Market is growing rapidly due to technological innovations, increased research funding, and a greater understanding of neurological conditions. With more developments on the horizon, this market presents substantial opportunities for investment and research.
Related reports:
Vascular Access Device Market
Veterinary Chemistry Analyzer Market
Veterinary Endoscope Market
0 notes
Text
Hypercoagulability: Market Insights, Competitive Landscape, and Forecast to 2032
Market Insights
The global hypercoagulability market is projected to grow significantly by 2032, fueled by rising awareness of coagulation disorders and increasing cases of venous thromboembolism (VTE), stroke, and pulmonary embolism (PE). Hypercoagulability refers to a heightened tendency for blood clot formation, which can result from genetic mutations, chronic diseases, cancer, immobility, or medication use, such as oral contraceptives and hormone therapy.
Key market drivers include the rising prevalence of cardiovascular diseases, obesity, and diabetes, along with the expanding elderly population. Additionally, the development of more effective diagnostics and safer anticoagulant drugs has increased the demand for preventive care. Increased adoption of personalized medicine and telehealth is also supporting patient monitoring and treatment compliance, further expanding the market potential.
Competitive Landscape
The hypercoagulability market features significant competition, with several global and regional pharmaceutical companies focusing on anticoagulant drug development, diagnostics, and treatment solutions. Key players include:
Pfizer Inc.
Bristol-Myers Squibb
Sanofi S.A.
Bayer AG
Daiichi Sankyo Company
These companies offer both traditional therapies like warfarin and newer direct oral anticoagulants (DOACs), including apixaban, rivaroxaban, and dabigatran. Innovations focus on reducing bleeding risks, a common side effect of anticoagulation therapies while maintaining efficacy. Diagnostic providers are also advancing screening tools like D-dimer tests and thromboelastography to enable early detection and more precise risk assessments.
Collaborations between pharmaceutical firms and healthcare providers are increasing to promote clinical trials and real-world studies that demonstrate the safety and efficiency of newer drugs. Moreover, regulatory bodies are streamlining approvals for therapies that reduce thrombotic events without compromising patient safety.
Forecast to 2032
By 2032, the hypercoagulability market is expected to expand at a steady compound annual growth rate (CAGR). North America and Europe will continue to lead due to established healthcare systems and early adoption of innovative solutions. Meanwhile, the Asia-Pacific region is projected to experience the fastest growth, driven by expanding healthcare access, rising awareness campaigns, and the increasing burden of chronic diseases.
Advances in diagnostics and personalized anticoagulants will remain central to market growth, with digital health technologies further enhancing treatment adherence. Governments and public health bodies are also expected to intensify screening programs, reducing complications associated with clotting disorders.
In conclusion, the hypercoagulability market offers strong growth potential over the next decade, shaped by technological innovation, evolving patient needs, and collaborative efforts among key industry stakeholders.
Latest Reports Offered By DelveInsight:
Aneurysmal Subarachnoid Hemorrhage Market | Angelman Syndrome Market | Autoimmune Pulmonary Alveolar Proteinosis Market | Cardiovascular Calcification Market | Charcot Marie Tooth Disease Market | Chronic Focal Epilepsy Market | Crispr Therapies- Pipeline Insights Market | Cytokine Release Syndrome Market | Frontotemporal Dementia Market | Glabellar Frown Lines Market | Graves Ophthalmopathy Market | Icos-next Generation Immunotherapy Market | Invasive Pneumococcal Disease Market | Lipodystrophy Market | Nasolabial Fold Market | Natural Killer T Cell Lymphoma Market | Nrg1 Fusion Cancer Market | Osteochondrodysplasias Market | Pachyonychia Congenita Market | Pegfilgrastim Biosimilar Insight | Salivary Gland Infection Market | Scedosporium Infection Market | Shoulder Replacement Devices Market | Single Ventricle Heart Disease Market | Spinal Decompression/traction Devices Market | Stuttering Market | Tenosynovitis Market
#Hypercoagulability#Hypercoagulability Market#Hypercoagulability Forecast#Hypercoagulability Companies#Hypercoagulability Drugs#Hypercoagulability Therapies#Hypercoagulability Epidemiology#Hypercoagulability Pipeline#Hypercoagulability Market Size#Hypercoagulability Market Trends
0 notes
Text
Clinical Trials Market Size, Share, Growth and Industry Trends 2024 - 2030
The global clinical trials market size was valued at USD 80.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030.
The market growth spiked in 2020 owing to the COVID-19 pandemic. This growth pattern was witnessed by both virtual clinical trials and traditional ones. Several companies invested heavily in novel drug development to minimize COVID-19 patient burden. One such example being, in 2020, Synairgen plc and Parexel collaborated on a Phase III study of Interferon-beta (IFN-beta) treatment for COVID-19. Furthermore, rapid technological evolution, rising prevalence of chronic diseases, globalization of clinical trials, penetration of personalized medicine and a rise in demand for CROs for conducting research activities is expected to positively impact the market growth.
In addition, the COVID-19 pandemic led to changing the ways of conducting upcoming or ongoing clinical trials. Regulatory agencies including the U.S. FDA, the European Medicines Agency (EMA), the National Institutes of Health (NIH), and China’s National Medical Products Administration among several others issued various guidelines for conducting trials during the pandemic to support the implementation of decentralized clinical trials and virtual services. The current scenario for research and development activities across the globe and the need for several new treatment options have also led to the adoption of fast-track clinical trials. Thus, aforementioned factors are estimated to offer new avenues to the clinical trials market growth.
Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market
Clinical Trials Market Report Highlights
• The phase III clinical trials segment dominated the market with a 53.3% share in 2023. This can be attributed to the complexity of this phase
• The interventional studies segment dominated the market in 2023. It is one of the most prominent methods used in clinical trials in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers
• North America held 50.3% of the market share in 2023. Favorable government initiatives and the presence of a large number of players in the U.S. that offer advanced services are responsible for market growth
• Asia Pacific region is anticipated to grow at the fastest CAGR over the forecast period owing to the increasing patient pool and cost-efficient services.
Browse through Grand View Research's Healthcare IT Industry Research Reports.
• The global healthcare predictive analytics market size was estimated at USD 14.58 billion in 2023 and is projected to grow at a CAGR of 24.0% from 2024 to 2030.
• The global medical animation market size was valued at USD 396.2 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 20.1% from 2024 to 2030.
Clinical Trials Market Segmentation
Grand View Research has segmented the global clinical trials market based on phase, study design, indication, sponsor, indication by study design, and region:
Clinical Trials Phase Outlook (Revenue, USD Billion, 2018 - 2030)
• Phase I
• Phase II
• Phase III
• Phase IV
Clinical Trials Study Design Outlook (Revenue, USD Billion, 2018 - 2030)
• Interventional
• Observational
• Expanded Access
Clinical Trials Indication by Study Design Outlook (Revenue, USD Billion, 2018 - 2030)
• Autoimmune/Inflammation
o Rheumatoid Arthritis
o Multiple Sclerosis
o Osteoarthritis
o Irritable Bowel Syndrome (IBS)
o Others
• Pain Management
o Chronic Pain
o Acute Pain
• Oncology
o Blood Cancer
o Solid Tumors
o Other
• CNS Condition
o Epilepsy
o Parkinson's Disease (PD)
o Huntington's Disease
o Stroke
o Traumatic Brain Injury (TBI)
o Amyotrophic Lateral Sclerosis (ALS)
o Muscle Regeneration
o Others
• Diabetes
• Obesity
• Cardiovascular
• Others
Clinical Trials Indication Outlook (Revenue, USD Billion, 2018 - 2030)
• Autoimmune/Inflammation
o Interventional
o Observational
o Expanded Access
• Pain Management
o Interventional
o Observational
o Expanded Access
• Oncology
o Interventional
o Observational
o Expanded Access
• CNS Condition
o Interventional
o Observational
o Expanded Access
• Diabetes
o Interventional
o Observational
o Expanded Access
• Obesity
o Interventional
o Observational
o Expanded Access
• Cardiovascular
o Interventional
o Observational
o Expanded Access
• Others
o Interventional
o Observational
o Expanded Access
Clinical Trials Sponsor Outlook (Revenue, USD Billion, 2018 - 2030)
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others
Clinical Trials Service Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Bioanalytical Testing Services
• Clinical Trial Data Management Services
• Others
Clinical Trials Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o U.K.
o Germany
o France
o Spain
o Italy
• Asia Pacific
o India
o Japan
o China
o Australia
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
o Colombia
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.
#Clinical Trials Market#Clinical Trials Market size#Clinical Trials Market share#Clinical Trials Market analysis#Clinical Trials Industry
0 notes
Text
Neuroscience Antibodies & Assay Market 2024 : Industry Analysis, Trends, Segmentation, Regional Overview And Forecast 2033
The neuroscience antibodies & assays global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Neuroscience Antibodies & Assays Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size - The neuroscience antibodies & assays market size has grown rapidly in recent years. It will grow from $4.1 billion in 2023 to $4.63 billion in 2024 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to research funding, drug discovery and development, neurodegenerative diseases, government initiatives, personalized medicine.
The neuroscience antibodies & assays market size is expected to see rapid growth in the next few years. It will grow to $7.68 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to collaborations, telemedicine in neurology, education and training, biomarker-driven therapies, neuroimmunology focus . Major trends in the forecast period include microrna and non-coding rna assays, digital pathology, advanced imaging-compatible assays, single-cell analysis, 3d organoid models.
Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/neuroscience-antibodies-and-assays-global-market-report
The Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Market Drivers -
The increase in incidents of neurological illnesses across the globe are expected to propel the growth of the neuroscience antibodies & assays market going forward. Neurological illnesses are disorders and affecting the nervous system, and examples of neurological disorders include epilepsy, Alzheimer’s disease, dementia, and so on. The rise in the number of neurological illnesses requires more research and development activities for the treatment of these diseases. Antibodies and assays are used in research and development activities to study development, systems, structure and function, and disorders and degeneration of the nervous system. Thus, the neuroscience antibodies & assays market grows with the increase in incidents of neurological illnesses. For instance, According to the World Health Organization, a Switzerland-based health promotion agency 55 million people live with dementia globally, and there are nearly 10 million new cases every year as per 2021 data. According to Alzheimer's Association a US based Non-profit association, 6.5 million people in the US have Alzheimer's disease as per 2022 data. As a result, the increased incidence of neurological illnesses across the world is driving the neuroscience antibodies and assays market forward.
The neuroscience antibodies & assays market covered in this report is segmented –
1) By Product: Consumables, Instruments 2) By Technology: Molecular Diagnostics, Clinical Chemistry, Immunoassays Or Immunochemistry, Others Technologies 3) By Application: In Vitro Diagnostics, Research, Drug Discovery 4) By End User: Hospitals And Diagnostics Centers, Academic And Research Institutes, Pharmaceutical And Biotechnology Companies
Get an inside scoop of the neuroscience antibodies & assays market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=7548&type=smp
Regional Insights - North America was the largest region in the neuroscience antibodies & assays market in 2023. The regions covered in the neuroscience antibodies & assays market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies - Major companies operating in the neuroscience antibodies & assays market include Abcam plc, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Merck KGaA, Rockland Immunochemicals Inc., GenScript Biotech Corporation, Santa Cruz Biotechnology Inc., Wak-Chemie Medical GmbH, Epitope Diagnostics Inc., Agilent Technologies, Bio-Techne Corporation, Creative Diagnostics, Enzo Life Sciences Inc., Jackson ImmunoResearch Laboratories Inc., Novus Biologicals LLC, OriGene Technologies Inc., Proteintech Group Inc., R&D Systems Inc., RayBiotech Inc., StressMarq Biosciences Inc., Synaptic Systems GmbH, Tocris Bioscience, Alomone Labs Ltd., AnaSpec Inc., Antibodies.com, Antibody Solutions, Arbor Assays, Uscn Life Science Inc., Zymo Research Corp., AAT Bioquest Inc., Abbexa Ltd., ACROBiosystems Inc., Active Motif Inc., AdipoGen Life Sciences, Advanced Targeting Systems Inc., AgriSera AB
Table of Contents 1. Executive Summary 2. Neuroscience Antibodies & Assays Market Report Structure 3. Neuroscience Antibodies & Assays Market Trends And Strategies 4. Neuroscience Antibodies & Assays Market – Macro Economic Scenario 5. Neuroscience Antibodies & Assays Market Size And Growth ….. 27. Neuroscience Antibodies & Assays Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
0 notes
Text
Making Waves: The Global Blood Brain Barrier Market Will Grow At Highest Pace Owing To Emerging Cell Transport Methods
The blood brain barrier (BBB) helps control the movement of substances between the blood and the brain. It protects the brain from fluctuations in plasma composition but also restricts the delivery of therapeutics to the central nervous system. Medicinal products cannot freely pass from the bloodstream into the brain as they would in other organs, and new methods are needed to transport therapeutics across the barrier. Research focuses on developing vectors such as liposomes, polymeric and viral nanoparticles that can ferry drugs across the selectively permeable barrier.
The Global Blood Brain Barrier Market is estimated to be valued at US$ 36.2 Mn in 2024 and is expected to exhibit a CAGR of 49% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the Global Blood Brain Barrier Market are Denali Therapeutics,JCR Pharmaceuticals,Cyclenium Pharma,Lauren Sciences,biOasis Technologies. Denali Therapeutics is a leader in developing intrathecal medicines for neurodegenerative diseases. JCR Pharmaceuticals focuses on delivering therapeutics directly to the brain and spinal cord.
The market is driven by the growing prevalence of brain disorders such as Alzheimer's, Parkinson's, brain cancer and epilepsy. According to the Alzheimer's Association, over 6 million Americans are living with Alzheimer's dementia in 2022 and this number is expected to rise dramatically in the coming decades. Effective treatment of brain conditions requires methods to cross the BBB.
Technological advancements are helping develop enhanced targeted delivery systems. Researchers are utilizing nanomedicine approaches with particles sized 10-200nm that can cross the BBB via receptor mediated transport or openings between endothelial cells. A focus on customized drug delivery using bioengineering tools opens new opportunities.
Market Trends
Liposomal drug delivery is gaining momentum as a non-invasive method to transport therapeutics across the BBB. Drugs encapsulated in liposomes have shown potential to treat brain tumors, neuroinflammation and brain metastases. Researchers are designing stealth liposomes coated with polymers that evade phagocytosis.
Modified viral vectors are emerging as efficient carriers for gene and cell therapies targeting brain diseases. Adeno-associated and lentiviral vectors are being utilized to deliver therapeutic genes selectively to neurons and glial cells in the brain. Companies are engineering cell-specific promoters to control transgene expression.
Market Opportunities
Personalized medicine approaches tailored to an individual's BBB permeability profile offer opportunities. Predicting drug entry into the brain based on molecular characteristics and patient biomarkers could enable precision dosing regimens.
The development of real-time monitoring systems to track drugs circulating in the brain microenvironment after crossing the BBB opens new opportunities for feedback-based dosage adjustments. Novel diagnostic tools may transform treatment efficacy evaluation.
Impact Of COVID-19 On The Global Blood Brain Barrier Market Growth
The COVID-19 pandemic significantly impacted the global blood brain barrier market. During the initial phases of the pandemic, neurological complications were reported among severe COVID-19 patients which highlighted the need for diagnosing and treating blood brain barrier related disorders. However, the lockdowns and social distancing measures imposed worldwide disrupted clinical trials and research activities of pharmaceutical companies working in this domain. Supply chain disruptions also affected the availability of raw materials required for developing novel drug delivery mechanisms targeting the blood brain barrier.
As the pandemic progressed, investments towards developing treatments for neuroinvasive aspects of COVID-19 infections increased. Several small biotech firms received funding to study the impact of SARS-CoV-2 virus on the blood brain barrier and chances of it crossing over to cause neurological damage. This boosted research activities focused on better understanding blood brain barrier pathophysiology under viral infections. Various diagnostics companies also launched novel imaging and fluid biomarker tests to aid evaluation of neuroinvasive potential in COVID patients.
With worldwide vaccination drives in progress, research momentum in the field has regained lost ground in post pandemic times. Pharmaceutical firms are accelerating clinical trials of different drug candidates aiming to cross the blood brain barrier. Investments are also being made to develop advanced drug delivery platforms including nanocarriers, prodrug formulations and enzyme mediated approaches. It is expected that the learnings from COVID-19 will strengthen therapeutic development targeting blood brain barrier related conditions in the coming years.
Geographical Concentration Of The Global Blood Brain Barrier Market
In terms of value, North America holds the major share of the global blood brain barrier market attributed to presence of prominent pharmaceutical companies and advanced healthcare research infrastructure in the region. Significant funding from both private and government bodies has propelled clinical research activities exploring novel diagnostics and treatment paradigms. For instance, the Blood-Brain Barrier Program launched by National Institute of Health is supporting various academic-industrial collaborations through grants.
Asia Pacific is the fastest growing regional market for blood brain barrier diagnostics and therapeutics. Improving healthcare investments, rising incidence of neurodegenerative disorders and increasing development of local biopharmaceutical capabilities are driving market growth. Countries like China, India and South Korea are emerging as innovation hubs with strong bioscience talent pools enabling indigenous research and manufacturing capacities. Supportive regulations by regulatory agencies are also encouraging global players to establish manufacturing and clinical trial centers in the Asia Pacific region.
Fastest Growing Region For The Global Blood Brain Barrier Market
Asia Pacific region holds the maximum growth potential for the global blood brain barrier market over the forecast period. This can be attributed to factors like:
- Rapid economic development and expansion of urban healthcare infrastructure in most APAC countries including India and China.
- Growing geriatric demographics and increasing prevalence of neurological conditions like Alzheimer's, Parkinson's disease resulting in higher disease burden.
- Supportive government policies promoting local R&D programs and making healthcare more accessible and affordable.
- Strong pipeline of novel biologics, prodrug formulations and neuroimaging agents with Asian pharma companies leveraging the region's low-cost manufacturing advantages.
- Increasing number of collaborative research projects involving Asian and international institutes propelling clinical trials of BBB crossing drug candidates.
- Rising healthcare expenditures creating a larger patient pool able to afford premium diagnostics and speciality therapeutics.
- Evolving regulations expediting approvals and ensuring product safety to encourage medical innovation. With such favourable macroeconomic and industrial factors in place, Asia Pacific will likely emerge as the key growth driver globally for blood brain barrier therapeutics and technologies in the future.
Get more insights on this topic: https://www.ukwebwire.com/global-blood-brain-barrier-market-is-estimated-to-witness-high-growth-owing-to-advancements-in-biotechnology/
Author Bio:
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights. (LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
What Are The Key Data Covered In This Global Blood Brain Barrier Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Global Blood Brain Barrier Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Global Blood Brain Barrier Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Global Blood Brain Barrier Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Global Blood Brain Barrier Market vendors
FAQ’s
Q.1 What are the main factors influencing the Global Blood Brain Barrier Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Global Blood Brain Barrier Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Global Blood Brain Barrier Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it
#Global Blood Brain Barrier Market Trend#Global Blood Brain Barrier Market Size#Global Blood Brain Barrier Market Information#Global Blood Brain Barrier Market Analysis#Global Blood Brain Barrier Market Demand
0 notes
Text
The Antiepileptic Drugs Market is projected to grow from USD 18,845 million in 2024 to USD 26,190.14 million by 2032, reflecting a compound annual growth rate (CAGR) of 4.20%.The antiepileptic drugs (AEDs) market plays a critical role in the treatment and management of epilepsy, a neurological disorder characterized by recurrent seizures. With millions of people affected by epilepsy globally, the demand for effective antiepileptic medications continues to rise. The AED market has seen significant growth in recent years, driven by advancements in drug development, increased awareness, and an expanding patient population.
Browse the full report at https://www.credenceresearch.com/report/antiepileptic-drugs-market
Market Overview
The global antiepileptic drugs market has witnessed substantial growth over the past decade, and this trend is expected to continue. According to recent market reports, the market is projected to reach a valuation of USD 22.8 billion by 2030, growing at a compound annual growth rate (CAGR) of around 3.8% from 2023 to 2030. This growth can be attributed to several factors, including the increasing prevalence of epilepsy, the introduction of novel AEDs, and the growing awareness of epilepsy and its treatment options.
Key Drivers of Market Growth
1. Increasing Prevalence of Epilepsy: Epilepsy is one of the most common neurological disorders worldwide, affecting approximately 50 million people, according to the World Health Organization (WHO). The rising prevalence of epilepsy, particularly in low- and middle-income countries, is a major driver of the AED market. Factors such as genetic predisposition, infections, and head injuries contribute to the growing incidence of epilepsy.
2. Advancements in Drug Development: The AED market has benefited from significant advancements in drug development. In recent years, several new drugs have been approved for the treatment of epilepsy, offering improved efficacy and reduced side effects compared to older medications. These innovations have expanded the treatment options available to patients and have contributed to market growth.
3. Rising Awareness and Diagnosis: Increased awareness of epilepsy and its symptoms has led to earlier diagnosis and treatment. Public health campaigns, along with educational initiatives by healthcare organizations, have played a crucial role in raising awareness. Early diagnosis allows for timely intervention, reducing the risk of complications and improving patient outcomes.
4. Expanding Geriatric Population: The global population is aging, and the prevalence of epilepsy is higher among older adults. As the elderly population continues to grow, the demand for AEDs is expected to increase. Additionally, age-related comorbidities often require careful management, further driving the need for effective antiepileptic treatments.
Challenges and Opportunities
While the antiepileptic drugs market is poised for growth, it is not without its challenges. One of the primary challenges is the high cost of newer AEDs, which can limit access for patients, particularly in low-income regions. Additionally, the side effects associated with some AEDs can affect patient adherence to treatment, leading to suboptimal outcomes.
Despite these challenges, there are several opportunities for growth in the AED market. The development of personalized medicine and the increasing focus on precision medicine offer promising avenues for improving treatment efficacy. By tailoring therapies to individual patient profiles, healthcare providers can achieve better outcomes with fewer side effects. Moreover, ongoing research into the underlying mechanisms of epilepsy may lead to the discovery of new drug targets and innovative treatment approaches.
Regional Insights
The antiepileptic drugs market is geographically diverse, with North America, Europe, Asia-Pacific, and Latin America being the key regions. North America currently dominates the market, driven by a high prevalence of epilepsy, well-established healthcare infrastructure, and strong R&D activities. Europe follows closely, with a similar market structure.
In contrast, the Asia-Pacific region is expected to witness the fastest growth during the forecast period. The increasing awareness of epilepsy, improving healthcare infrastructure, and rising healthcare expenditure in countries like China and India are contributing to this growth. Additionally, government initiatives aimed at improving access to epilepsy treatment are expected to boost market expansion in this region.
Key Player Analysis
UCB S.A.
Eisai Co., Ltd.
Pfizer Inc.
Johnson & Johnson Service, Inc.
Merck KGaA
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Reddy’s Laboratories Ltd.
GlaxoSmithKline plc
AstraZeneca
Abbott
Segments:
Based on Drug Generation:
First-generation
Second-generation
Third-generation
Based on Route of Administration:
Oral
Intravenous
Based on Distribution Channel:
Hospital pharmacies
Retail pharmacies
Online pharmacies
Drug stores
Based on the Geography:
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Browse the full report at https://www.credenceresearch.com/report/antiepileptic-drugs-market
About Us:
Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.
Contact:
Credence Research
Please contact us at +91 6232 49 3207
Email: [email protected]
Website: www.credenceresearch.com
0 notes
Text
Medicinal Cannabis Market Driving Growth Owing to Increased Legalization
Medicinal cannabis, also known as medical marijuana, refers to using the whole unprocessed marijuana plant or its basic extracts to treat symptoms of illnesses and other conditions. It is most commonly used to treat chronic pain, muscle spasms, nausea caused by chemotherapy, neurological disorders, epilepsy, and mental disorders such as depression, anxiety and post-traumatic stress disorder. The legalization of medicinal cannabis across various countries is fueling its demand as an alternative to prescribed medication to treat medical ailments.
The Global Medicinal Cannabis Market is estimated to be valued at US$ 14589.08 Bn in 2024 and is expected to exhibit a CAGR of 13.% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the Medicinal Cannabis Market are Deere & Company, AGCO Corporation, Agribotix LLC, Agrobot and Blue River Technology. These players are focusing on introducing advanced technologies for cultivation and production of cannabis to meet the growing demand. The key opportunities in the market include expanding product portfolio, strategic partnerships, and increasing geographical presence. Various countries are legalizing cannabis for medical use which is creating new opportunities for market players. Technological advancements such as controlled environment agriculture, artificial intelligence, indoor farming, and analytics are enabling efficient cultivation of cannabis. Smart greenhouses with sensors and robotic equipment are helping increase yield while reducing production costs. Market Drivers Increased legalization of medicinal cannabis across major countries is a key driver boosting the market growth. Countries like Canada, Germany, Italy, Australia, Chile, Colombia, and several U.S. states have legalized medical cannabis over the past decade. This has expanded access to patients and increased production. Growing acceptance of cannabis in treating health issues is further fueling the demand. Rising investments in development of advanced cannabis varieties through plant breeding is also propelling the market.
Current Challenges in Medicinal Cannabis Market The Medicinal Cannabis Market Demand is still evolving with various challenges. One major challenge is the variable legality and regulations across different geographies. While many countries and states have legalized medical cannabis, it is still considered as an illegal drug in others. This regulatory uncertainty poses difficulty for businesses to expand globally and gain acceptance. Another challenge is the limited number of high-quality clinical studies to prove the medical efficacy and advantages of various cannabis-based medicines. More extensive research is still needed to understand the potential of cannabis-based therapeutics better. On the production front, developing standardized cultivation and manufacturing practices is challenging due to the complexity involved. This impacts the consistency and quality of medical cannabis products. Lastly, with medical cannabis being a new category, its acceptance among medical professionals and patients is still a work in progress which requires more awareness and advocacy.
Get more insights on Medicinal Cannabis Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
0 notes
Text
Medical Marijuana Market 2024 Global Key Players Analysis, Size, Trend, Growth and Forecast 2032
According to a new report by SNS Insider, the global medical marijuana market is poised for remarkable growth, driven by increasing legalization, expanding therapeutic applications, and growing awareness of cannabis-based treatments. The Medical Marijuana Market Revenue is expected to see significant growth as healthcare providers, researchers, and policymakers recognize the potential benefits of cannabis-derived treatments for chronic conditions such as pain, epilepsy, and mental health disorders.
The report underscores the crucial role of regulatory shifts and the global push toward legalized medical marijuana, which has spurred significant research investments and product innovations within the sector. Countries across North America, Europe, and parts of Asia-Pacific have enacted or are in the process of implementing policies that decriminalize and regulate the medical use of marijuana, creating a conducive environment for market growth. Furthermore, the adoption of cannabis in healthcare has shown to enhance quality of life for patients by offering a viable alternative to traditional pharmaceutical treatments, especially for chronic and palliative care patients.
Medical marijuana has shown to be effective in treating an array of conditions, including but not limited to chronic pain, cancer-related symptoms, neurological disorders, and even some mental health conditions. Its growing popularity in both developed and emerging economies is driving the expansion of the industry. With increased public and private sector support, the medical marijuana market is expected to continue growing rapidly, creating lucrative opportunities for stakeholders across the pharmaceutical, biotech, and healthcare sectors.
Get Free Sample Report@ https://www.snsinsider.com/sample-request/3511
Market Insights and Key Findings
The SNS Insider report highlights several key factors contributing to the growth of the medical marijuana market. Increased research funding, coupled with a favorable legal framework, has facilitated the development of cannabis-based medical products. The market is currently dominated by North America, with the United States and Canada leading in terms of legal adoption and advanced medical research. However, Europe and parts of Asia-Pacific are anticipated to gain traction, driven by shifts in public perception and more flexible regulatory policies.
Technological advancements are also playing a critical role in the evolution of the medical marijuana market. Innovations in cultivation, extraction, and formulation are improving the potency, efficacy, and purity of cannabis-based products. The emergence of digital health platforms is further expanding accessibility, allowing patients to consult with healthcare professionals and receive prescriptions for medical marijuana in a safe and convenient manner. The report also highlights the growing trend of e-commerce, enabling consumers to purchase cannabis-based treatments online, which has particularly gained momentum during the COVID-19 pandemic.
In terms of segmentation, the market includes products such as oils, tinctures, and edibles, with oils representing a significant portion of sales due to their potency and ease of use. End-user demand from the pharmaceutical sector and healthcare providers remains robust, driven by increasing patient preference for natural, plant-based treatments over synthetic drugs. The report also forecasts strong demand in the pain management segment, particularly for managing symptoms in chronic pain patients and those undergoing cancer treatment.
Challenges and Opportunities
While the medical marijuana market holds immense potential, it also faces several challenges. Regulatory inconsistencies, especially between federal and state laws in some countries, pose significant barriers. Moreover, the lack of standardized guidelines for dosage and quality control adds to the complexity of market operations. Nonetheless, ongoing research, favorable shifts in public opinion, and active lobbying by patient advocacy groups are expected to mitigate these challenges over time.
In addition, the global focus on mental health is opening new avenues for the medical marijuana market. Studies have demonstrated the potential of cannabis-based treatments in managing mental health conditions such as anxiety, PTSD, and depression. With the World Health Organization and other influential bodies highlighting the importance of mental health, there is a burgeoning interest in exploring medical marijuana as a safe, effective, and affordable treatment alternative.
Future Prospects
The medical marijuana market’s growth trajectory is projected to remain strong over the next decade, with the industry expected to attract increased investment from both the public and private sectors. The demand for alternative therapeutic options, combined with continuous advancements in cannabis research and product innovation, will likely contribute to sustained market expansion. This market offers substantial opportunities not only for established players but also for new entrants and startups focused on niche applications within medical marijuana.
In conclusion, the medical marijuana market represents one of the most dynamic segments within the healthcare sector. As regulations become more favorable, patient demand continues to increase, and technology drives innovation, the industry is set to flourish, presenting a range of opportunities for healthcare providers, researchers, manufacturers, and investors. For those looking to capitalize on the growth of this market, now is the time to invest in the rapidly evolving landscape of medical marijuana.
About Us
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us: Akash Anand – Head of Business Development & Strategy [email protected] Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)
#Medical Marijuana Market#Medical Marijuana Market Size#Medical Marijuana Market Share#Medical Marijuana Market Growth#Market Research
0 notes
Text
Catheters Market to Reach US$54.68 Bn by 2024 Owing to Growing Geriatric Population
The catheters market has witnessed substantial growth owing to increased prevalence of target diseases and growth in the geriatric population who are more prone to chronic diseases requiring long-term treatment. Catheters are medical tubes that can be inserted in the body to treat diseases or perform a surgical procedure. Catheters are increasingly being used in situations like urinary incontinence, cardiovascular diseases, neurovascular diseases, and urological surgeries. Catheters play an important role in medical procedures by enabling drainage, infusion of fluids, access, or pressure monitoring. The Global Catheters Market is estimated to be valued at US$ 54.68 Bn in 2024 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030. Key Takeaways Key players operating in the catheters market are Medtronic, ConvaTec, Inc., Smith Medical (Smith Group Plc.), Boston Scientific Corporation, Hollister Incorporated, and Edwards Lifesciences Corporation, among others. These players are focused on leveraging opportunities posed by the epilepsy treatment market through collaborations and partnerships with other players as well as expansion in emerging geographies. The growing geriatric population and their increasing vulnerability to various illnesses has augmented the demand for catheters globally. Advancements in catheter technology and material such as hydrophilic coatings, drugs coated on catheter surfaces to prevent infection and blockages, and safety engineered catheters has improved outcomes for various catheter-based procedures. Market Trends The trend of minimally invasive procedures has gained traction in the catheters market. Catheters are increasingly being used in minimally invasive surgeries as they reduce recovery time, trauma, and risks associated with open surgeries. Catheters are used in catheter-based ablation and angioplasty to treat cardiovascular diseases. Growing adoption of antimicrobial coatings on catheters is another key trend. Catheters coated with antibiotics, silver, or other compounds prevent infections of catheter sites and reduce healthcare costs associated with treatment and extended hospital stays. Market Opportunities Rising disease incidence rates especially of aging-related chronic illnesses in developing countries presents lucrative opportunities. The market players are focusing their efforts on these emerging economies. Growing demand for home healthcare and ambulatory services also creates opportunities for Foley catheters and vascular access catheters that can facilitate long-term treatment at home. Development of bioabsorbable catheters that dissolve and do not require removal post-procedure also has strong prospects. Impact of COVID-19 on Catheters Market Growth The outbreak of the COVID-19 pandemic has negatively impacted the growth of the global catheters market. During the initial lockdown imposed across various countries, all non-essential medical procedures and surgeries were postponed or canceled to focus medical resources on COVID patients. This resulted in a steep decline in the demand for various types of catheters used in surgeries and procedures. Moreover, supply chains were disrupted worldwide due to transportation restrictions imposed during lockdowns. This led to shortages and delays in the supply of raw materials for catheter manufacturing. However, with the lifting of lockdowns in 2021, the demand for catheters started recovering. Certain types of invasive procedures saw increased demand as patients sought them to avoid deterioration in their health conditions. The focus also shifted to developing catheters that aid in COVID treatment. For instance, feeding tubes are being used to supply nutrition to critically ill patients on ventilators.
0 notes
Text
Regional Analysis of Epilepsy Surgery Market Size
The Epilepsy Surgery Market Size was valued at USD 980 million in 2022 and is expected to reach USD 1483.5 million by 2030 and grow at a CAGR of 5.32% over the forecast period 2023-2030.The Epilepsy Surgery Market is witnessing significant growth, driven by advancements in surgical techniques and a rising prevalence of drug-resistant epilepsy cases. Innovations such as minimally invasive procedures and robotic-assisted surgeries are enhancing patient outcomes, reducing recovery times, and minimizing complications. Additionally, increasing awareness among patients and healthcare providers about the benefits of surgical intervention, along with improved diagnostic tools, is propelling market expansion.
Get Sample Of This Report @ https://www.snsinsider.com/sample-request/2575
Market Scope & Overview
The global market research report includes a strategy analysis that can be used by both new and established organisations to get market traction. To help businesses in their international expansion, market research gathers a thorough qualitative and quantitative assessment of the Epilepsy Surgery Market in the future. The key industry sectors covered by the market report are in-depth examined in the research report.
Epilepsy Surgery Market research, which offers crucial information based on the state of the worldwide market, can be useful for people and organisations interested in the target business. This market study looks at recent and upcoming changes in the sector.
Market Segmentation Analysis
By Procedure Type
Resective Surgery
Laser Interstitial Thermal Therapy (LITT)
Others
By End User
Hospitals & Clinics
Specialty Centers
Others
Russia-Ukraine War Impact on Epilepsy Surgery Market
The research delves further into how the Russian-Ukraine situation has impacted the global market. Despite the fact that tensions between Russia and Ukraine have been rising for years, the latest military action in Ukraine raises fears about market and global economic ramifications, as well as the possibility of a protracted conflict.
Regional Analysis
The research includes a thorough statistical analysis as well as an in-depth evaluation of the market from a global standpoint, including revenue, expenses, demand, and supply. The global market research was put together using data from a comprehensive market investigation and input from business experts. The global Epilepsy Surgery Market research report provides applications, definitions, and manufacturing technologies in addition to a study of global and regional markets.
Competitive Scenario
The analysis concentrates on the leading rivals in the Epilepsy Surgery Market industry. The market also pays close attention to the major firms' expansion goals. The market potential and present trends of the chosen industry are also assessed by this research. The pricing, interview data, gross profit, shipping, revenue, and company distribution are all included in the market analysis so that customers can better grasp the global marketplace. The top service providers around the world are also examined in this research report.
Key Reasons to Purchase Epilepsy Surgery Market Report
An overview of the sector and a number of prospective business possibilities are provided in the global market report.
The market research report makes it possible to thoroughly examine a variety of issues, from current events to new trends.
Conclusion
The research makes use of historical data and estimates in order to provide reasonable Epilepsy Surgery Market insights and a deeper understanding of the industry. Participants in the sector may be able to recognise and seize on current market possibilities with the use of these insights.
About US
SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.
When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.
Related Reports
Genomics Services Industry
Analgesics Industry
Immunomodulators Industry
Glaucoma Therapeutics Industry
DNA Synthesis Industry
0 notes
Text
Epilepsy Devices Market: Tech Trends 2022-2028
According to the WHO, epilepsy is a chronic brain disorder that affects 50 million individuals, making it one of the most prevalent neurological conditions worldwide. It is estimated that with access to early detection and appropriate care, 70% of the population diagnosed with epilepsy may live seizure-free. According to our estimates, the global epilepsy devices market was valued at $669.73 million in 2021 and is expected to reach $1157.58 million by 2028, growing at a CAGR of 8.16% during the forecast period 2022-2028.
Government institutions worldwide are focused on starting initiatives to create innovative epilepsy devices with AI and machine learning integration. Additionally, organizations that support research need to encourage high-quality comparative efficacy trials and sufficient data to guide therapeutic practice in epilepsy. As a result of these technologically advanced equipment and increasing drug trials, the market for epilepsy devices is anticipated to grow throughout the forecast period.
Epilepsy Devices - Key Detection Methodologies
Currently, several wearable technologies can detect seizures, collect data, and alert caregivers. Although with technological advancements, the ability to detect seizure-related alterations increases. Top trends backing this tech boom include:
Wearable devices are estimated to be the fastest-growing device type during the forecast period. Monitoring epileptic patients is crucial, as 20% of epileptics only have seizures while asleep, 40% only have seizures while awake, and 35% have seizures both when they are awake and asleep. With technologically advanced non-invasive wearable sensors, measuring accelerometry, photoplethysmography (PPG), electrodermal activity (EDA), electromyography (EMG), and other signals outside of the conventional clinical environment have become effective.
Vagus Nerve Stimulation (VNS) has emerged as the fastest-growing application category. VNS Therapy has been approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy for age 4 years and above to treat drug-resistant epilepsy or refractory epilepsy. VNS has been reportedly beneficial in many patients, including the ones with posttraumatic epilepsy (PTE). PTE is a common consequence of traumatic brain injury and accounts for about 20% of symptomatic epilepsy cases.
As per estimates, Electroencephalography lead the detection and prediction devices type segment in 2021 and is expected to maintain its stronghold during the forecast period. There is growing interest in wearable or mobile EEG solutions that allow long‐term EEG monitoring in an easy‐to‐use format. Despite the availability of these new EEG solutions, their adoption is still limited in clinical practice, mainly because of the unfamiliarity of healthcare and biomedical research sectors with the technology and its application.
Strategic Initiatives and Government Approvals
Different end-users, such as homecare settings, hospitals, and clinics, are utilizing epilepsy devices. The manufacturers of epilepsy monitoring devices are likely to gain prominent business opportunities from the hospital & clinics segment owing to the rise in the use of EEG monitoring and emergency medical services.
The government authorities of several developing nations, including India and China, are focusing on developing sturdy healthcare infrastructure. As a result, operating players are expected to gain sizable growth prospects in the region during the forecast period. Owing to this, the Asia Pacific epilepsy devices market is anticipated to witness the fastest growth with a CAGR of 8.38% throughout the forecast period.
In addition, companies are also focusing on launching novel devices for children. Moreover, companies are also using organic and inorganic strategies, including mergers and acquisitions, to stay ahead of the competition. Some of these include:
In September 2022, Boston Scientific Corporation’s current-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use labeling. The company also received FDA 510(k) clearance for the EMBOLD Fibered Detachable Coil, which reduces the blood flow rate in the peripheral vasculature.
In July 2022, Medtronic PLC received FDA 510(k) clearance for its UNiD Spine Analyzer v4.0 planning platform to leverage machine learning.
In November 2021, NeuroPace, Inc. received an Investigational Device Exemption (IDE) from the FDA to study the company’s RNS System to treat primary generalized epilepsy in patients aged 12 and above.
Way Forward
With technological advancements, epilepsy detection devices with exceptionally low false alarm rates have recently been developed. They are based on computationally intensive algorithms and employed in implanted systems for pre-surgical monitoring. Recent research has produced encouraging findings for probabilistic seizure risk projections using long-term wearable technology and electronic seizure diaries. The symptoms, mood, and cognitive function of an individual may also have predictive significance. Therefore, technological advances in non-invasive wearable sensors are anticipated to create growth opportunities for the epilepsy devices market.
FAQ:
Q1) What are the key end-users of the epilepsy devices market?
The key end-users in the epilepsy devices market include hospitals & clinics, neurology centers, homecare settings, and other end-users.
Q2) Which region leads the global epilepsy devices market?
North America leads the global epilepsy devices market.
#Epilepsy Devices Market#Epilepsy Devices#Lifesciences#Medical Devices & Consumables#triton market research#market research reports
0 notes
Text
Antiepileptic Drug Market Trends, Analysis and Forecast
The global antiepileptic drug (AED) market is projected to grow at a CAGR of around 2% from 2021 to 2027. This growth is fueled by the continuous development of new drugs and increasing research efforts to produce more specific and effective treatments for epilepsy. According to the World Health Organization (WHO), epilepsy affects approximately 50 million people worldwide, making it one of the most prevalent neurological disorders globally.
Key Market Drivers:
1. Increasing Prevalence of Epilepsy: With around 50 million people affected globally, the demand for effective AEDs is substantial. The increasing incidences of other neurological disorders and prenatal injuries also contribute to the rising number of epilepsy cases.
2. Advancements in Drug Development: Ongoing research and development efforts aim to create more effective and targeted AEDs. This innovation is crucial for enhancing patient outcomes and minimizing the side effects of existing treatments.
3. Impact of COVID-19: The pandemic has had a mixed impact on the market. While the financial stability of the private healthcare sector was challenged, leading to delays in clinical trials and research, the ongoing need for effective epilepsy treatments remains unchanged, driving demand in the long term.
For a comprehensive analysis of the market drivers, visit https://univdatos.com/report/antiepileptic-drug-market/
Market Segmentation:
1. By Drug Class:
- First Generation: Established treatments with a long history of use.
- Second Generation: Held a significant market share in 2020 due to their efficacy in slowing brain impulses and controlling seizures.
- Third Generation: Represents the latest advancements in AEDs, focusing on improved efficacy and reduced side effects.
2. By Distribution Channel:
- Retail Pharmacies: Traditional brick-and-mortar outlets.
- Hospital Pharmacies: Integral to in-hospital treatment and ongoing patient care.
- Online Pharmacies: Expected to witness significant growth due to the increasing penetration of e-pharmacy platforms and rising awareness of their benefits.
Regional Insights:
- North America: Dominates the market due to the high prevalence of epilepsy, with about 1.2% of the U.S. population having active epilepsy. The region's developed healthcare infrastructure and the presence of major pharmaceutical companies contribute to its leading market position.
- Europe: Significant market share due to advanced healthcare systems and substantial investments in healthcare research and development.
- Asia-Pacific: Rapidly growing market driven by increasing healthcare access, rising awareness, and improving economic conditions.
Major Market Players:
Key players in the global AED market include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Zogenix, Dr. Reddy’s Laboratories Ltd., Alkem Labs, SK Biopharmaceuticals, and Eisai Co. These companies are engaged in various strategic initiatives such as mergers, acquisitions, and partnerships to develop new and advanced antiepileptic drugs.
For a sample report, visit https://univdatos.com/get-a-free-sample-form-php/?product_id=22772
Conclusion:
The global antiepileptic drug market is set to experience steady growth over the forecast period, driven by the increasing prevalence of epilepsy, advancements in drug development, and the expansion of online pharmacy platforms. Despite challenges posed by the COVID-19 pandemic, the ongoing demand for effective AEDs ensures continued market growth.
Contact Us:
UnivDatos Market Insights
Email - [email protected]
Contact Number - +1 9782263411
Website -www.univdatos.com
#Antiepileptic Drug Market#Antiepileptic Drug Market Size#Antiepileptic Drug Market Growth#Antiepileptic Drug Market Forecast
0 notes